Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

ClinicalTrials.gov ID: NCT02301234

Public ClinicalTrials.gov record NCT02301234. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee

Study identification

NCT ID
NCT02301234
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
111 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Fulranumab 1 mg Drug
  • Fulranumab 3 mg Drug
  • Celecoxib 100 mg Drug
  • Celecoxib 100 mg Matching Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 24, 2015
Primary completion
Sep 18, 2016
Completion
Sep 18, 2016
Last update posted
Sep 13, 2017

2015 – 2016

United States locations

U.S. sites
32
U.S. states
16
U.S. cities
32
Facility City State ZIP Site status
Not listed Glendale Arizona
Not listed Phoenix Arizona
Not listed Tucson Arizona
Not listed Little Rock Arkansas
Not listed Anaheim California
Not listed Garden Grove California
Not listed Los Angeles California
Not listed North Hollywood California
Not listed Boulder Colorado
Not listed Coral Gables Florida
Not listed Miami Florida
Not listed Orlando Florida
Not listed Winter Park Florida
Not listed Columbus Georgia
Not listed Chicago Illinois
Not listed Overland Park Kansas
Not listed Elkridge Maryland
Not listed Detroit Michigan
Not listed St Louis Missouri
Not listed Brooklyn New York
Not listed New York New York
Not listed Norman Oklahoma
Not listed Knoxville Tennessee
Not listed Memphis Tennessee
Not listed Tullahoma Tennessee
Not listed Arlington Texas
Not listed Houston Texas
Not listed Lampasas Texas
Not listed Nassau Bay Texas
Not listed Sugar Land Texas
Not listed Arlington Virginia
Not listed Charlottesville Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02301234, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 13, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02301234 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →